Cargando…

Cutaneous Mastocytosis with Persistent Blistering: Successful Treatment with Methylprednisolone and 3-Year Follow-Up Management

BACKGROUND: Mastocytosis is a rare disorder with diverse clinical manifestations. In cutaneous mastocytosis the mast cell infiltration is limited to the skin, but is often associated with systemic symptoms due to the release of mast cell mediators. CASE REPORT: We report a 6-month-old male infant wh...

Descripción completa

Detalles Bibliográficos
Autores principales: Yankova, Rumyana, Abadjieva, Tsvetana, Belovezhdov, Veselin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4470957/
https://www.ncbi.nlm.nih.gov/pubmed/25876210
http://dx.doi.org/10.1007/s13555-015-0073-6
_version_ 1782376824802639872
author Yankova, Rumyana
Abadjieva, Tsvetana
Belovezhdov, Veselin
author_facet Yankova, Rumyana
Abadjieva, Tsvetana
Belovezhdov, Veselin
author_sort Yankova, Rumyana
collection PubMed
description BACKGROUND: Mastocytosis is a rare disorder with diverse clinical manifestations. In cutaneous mastocytosis the mast cell infiltration is limited to the skin, but is often associated with systemic symptoms due to the release of mast cell mediators. CASE REPORT: We report a 6-month-old male infant who had skin lesions of various morphologies (macules, papules, plaques, and nodules) and sizes, persistent blistering and frequent flushing episodes for half a year. Vital signs and physical examinations were unremarkable. No abnormalities in the laboratory tests were found except for a serum tryptase level (STL) of 11.8 ng/ml. The histological and immunohistochemical examinations confirmed the diagnosis of cutaneous mastocytosis. The patient was first treated with methylprednisolone, oral levocetirizine, and topical fusidic acid/betamethasone cream. Subsequently the treatment was tapered and stopped within 9 weeks. The child’s symptoms improved and were successfully controlled with intermittent courses of ketotifen and topical hydrocortisone over 3 years. CONCLUSION: Childhood cutaneous mastocytosis usually has a favorable prognosis, but in some cases the disease can progress with skin manifestations necessitating a more active systemic and topical treatment. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1007/s13555-015-0073-6) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-4470957
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher Springer Healthcare
record_format MEDLINE/PubMed
spelling pubmed-44709572015-06-22 Cutaneous Mastocytosis with Persistent Blistering: Successful Treatment with Methylprednisolone and 3-Year Follow-Up Management Yankova, Rumyana Abadjieva, Tsvetana Belovezhdov, Veselin Dermatol Ther (Heidelb) Case Report BACKGROUND: Mastocytosis is a rare disorder with diverse clinical manifestations. In cutaneous mastocytosis the mast cell infiltration is limited to the skin, but is often associated with systemic symptoms due to the release of mast cell mediators. CASE REPORT: We report a 6-month-old male infant who had skin lesions of various morphologies (macules, papules, plaques, and nodules) and sizes, persistent blistering and frequent flushing episodes for half a year. Vital signs and physical examinations were unremarkable. No abnormalities in the laboratory tests were found except for a serum tryptase level (STL) of 11.8 ng/ml. The histological and immunohistochemical examinations confirmed the diagnosis of cutaneous mastocytosis. The patient was first treated with methylprednisolone, oral levocetirizine, and topical fusidic acid/betamethasone cream. Subsequently the treatment was tapered and stopped within 9 weeks. The child’s symptoms improved and were successfully controlled with intermittent courses of ketotifen and topical hydrocortisone over 3 years. CONCLUSION: Childhood cutaneous mastocytosis usually has a favorable prognosis, but in some cases the disease can progress with skin manifestations necessitating a more active systemic and topical treatment. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1007/s13555-015-0073-6) contains supplementary material, which is available to authorized users. Springer Healthcare 2015-04-15 /pmc/articles/PMC4470957/ /pubmed/25876210 http://dx.doi.org/10.1007/s13555-015-0073-6 Text en © The Author(s) 2015 https://creativecommons.org/licenses/by-nc/4.0/This article is distributed under the terms of the Creative Commons Attribution Noncommercial License which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and the source are credited.
spellingShingle Case Report
Yankova, Rumyana
Abadjieva, Tsvetana
Belovezhdov, Veselin
Cutaneous Mastocytosis with Persistent Blistering: Successful Treatment with Methylprednisolone and 3-Year Follow-Up Management
title Cutaneous Mastocytosis with Persistent Blistering: Successful Treatment with Methylprednisolone and 3-Year Follow-Up Management
title_full Cutaneous Mastocytosis with Persistent Blistering: Successful Treatment with Methylprednisolone and 3-Year Follow-Up Management
title_fullStr Cutaneous Mastocytosis with Persistent Blistering: Successful Treatment with Methylprednisolone and 3-Year Follow-Up Management
title_full_unstemmed Cutaneous Mastocytosis with Persistent Blistering: Successful Treatment with Methylprednisolone and 3-Year Follow-Up Management
title_short Cutaneous Mastocytosis with Persistent Blistering: Successful Treatment with Methylprednisolone and 3-Year Follow-Up Management
title_sort cutaneous mastocytosis with persistent blistering: successful treatment with methylprednisolone and 3-year follow-up management
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4470957/
https://www.ncbi.nlm.nih.gov/pubmed/25876210
http://dx.doi.org/10.1007/s13555-015-0073-6
work_keys_str_mv AT yankovarumyana cutaneousmastocytosiswithpersistentblisteringsuccessfultreatmentwithmethylprednisoloneand3yearfollowupmanagement
AT abadjievatsvetana cutaneousmastocytosiswithpersistentblisteringsuccessfultreatmentwithmethylprednisoloneand3yearfollowupmanagement
AT belovezhdovveselin cutaneousmastocytosiswithpersistentblisteringsuccessfultreatmentwithmethylprednisoloneand3yearfollowupmanagement